| Literature DB >> 30112408 |
Marie Reisener1, Carsten Perka1.
Abstract
BACKGROUND: Culture-negative periprosthetic joint infections (CN PJI) have not been well studied, and due to the lack of consensus on PJI, especially with culture-negative infections, there are considerable uncertainties. Due to the challenging clinical issue of CN PJI the aim of this systematic review is to describe incidence, diagnosis, and treatment outcomes based on the current literature on CN PJI. HYPOTHESIS: The review is designed to assess the formal hypothesis that CN PJI of the hip and knee have a poorer outcome when compared with culture-positive ones. STUDYEntities:
Mesh:
Year: 2018 PMID: 30112408 PMCID: PMC6077559 DOI: 10.1155/2018/6278012
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Search strategy.
|
|
|
|---|---|
| #1 | periprosthetic infection or periprosthetic joint infection or surgical wound infection or prosthesis-related infection |
|
| |
| #2 | knee arthroplasty or total knee arthroplasty or knee replacement or knee prosthesis or arthroplasty, replacement, knee |
|
| |
| #3 | hip arthroplasty or total hip arthroplasty or hip replacement or hip prosthesis or arthroplasty, replacement, hip |
|
| |
| #4 | Culture negative OR culture |
|
| |
| #6 | #1 AND #2 AND #4 |
|
| |
| #7 | #1 AND #3 AND #4 |
Data sheet for comparative analysis [15–22].
| Author | Li H et al. | Choi HR et al. | Ibrahim MS et al. | Huang R et al. | Berbari EF et al. | Malekzadeh D et al. | Kim YH et al. | Kim YH et al. |
|---|---|---|---|---|---|---|---|---|
| Title | Two-stage revisions for culture-negative infected total knee arthroplasties: A five-year outcome in comparison with one-stage and two-stage revisions for culture-positive cases. | Periprosthetic joint infection with negative culture results: Clinical characteristics and treatment outcome. | Two-stage revision for the culture-negative infected total hip arthroplasty. | Culture-negative periprosthetic joint infection does not preclude infection control. | Culture-negative Prosthetic Joint Infection. | Prior Use of Antimicrobial Therapy is a Risk Factor for Culture-negative Prosthetic Joint Infection. | Comparison of infection control rates and clinical outcomes in culture-positive and culture-negative infected total-knee arthroplasty. | The outcome of infected total knee arthroplasty: culture-positive versus culture-negative. |
|
| ||||||||
| Year | 2017 | 2013 | 2017 | 2012 | 2007 | 2010 | 2015 | 2015 |
|
| ||||||||
| Country | Netherlands | United States | UK | United States | United States | United States | Korea | Korea |
|
| ||||||||
| LoE | III | III | III | III | III | III | III | III |
|
| ||||||||
| Study design | Retrospective | Retrospective | Prospective | Retrospective | Retrospective | Retrospective | Retrospective | Retrospective |
|
| ||||||||
| Study Type | Case-Control study | Case-Control study | Case-Control study | Case-Control study | Cohort study | Case-Control study | Case-Control study | Case-Control study |
|
| ||||||||
| Treatment interval | 2003-2014 | 2000-2009 | 2007-2012 | 2000-2007 | 1990-1999 | 1985-2000 | 2001-2008 | 1991-2008 |
|
| ||||||||
| Total number of cases | 129 | 175 | - | 295 | 897 | 1413 | 242 | 191 |
|
| ||||||||
| Prevalence of CN cases % | 14.2 | 23 | - | 16.3 | 7 | 10.5 | 42.1 | 26.7 |
|
| ||||||||
| Hip % | - | 50 | 100 | 43.8 | 45 | 50 | - | - |
|
| ||||||||
| Knee % | 100 | 50 | - | 56.2 | 55 | 50 | 100 | 100 |
|
| ||||||||
| FU in months, median | 55.6 | 52 | 60 | 47 | 36-60 | 56 | 127.2 | 127.2 |
|
| ||||||||
| Risk factors | - | (1) prior use of antibiotics | (1) prior use of antibiotics (within 3 months) | (1) prior use of antibiotics (in 64%) | - | - | ||
|
| ||||||||
| Debridement n | - | 11 | - | 12 | 12 | 18 | 56 | 28 |
|
| ||||||||
| 1-stage n | 3 | 5 | 8 | - | - | |||
|
| ||||||||
| 2-stage n | 18 | 23 | 50 | 33 | 34 | 56 | 46 | 23 |
|
| ||||||||
| Permanent resection n | - | - | - | 8 | 34 | - | - | |
|
| ||||||||
| Other therapy | 6 | - | - | 1 | 19 | - | - | |
|
| ||||||||
| Antibiotic treatment after diagnosis % | Vancomycin 33 Vancomycin + Ceftriaxone 33 Others 34 | Vancomycin 70; Others 30 | - | Vancomycin 81; Cephalosporins 10; Others 9 | Cephalosporins 82; Vancomycin 12; Others 6 | Cefazolin 69; Vancomycin 13; Others/None 18 | Vancomycin 85; Others 15 | Vancomycin 86; Others 14 |
|
| ||||||||
| Successful treatment in % | 88,9 | 85 | 94 | - | - | - | 95 | 95 |
|
| ||||||||
| Overall infection free survival rate % | - | - | 1.) - | 73 | - | 1.) - | - | - |
|
| ||||||||
| I&D infection free survival rate % | - | - | - | 50 | 1.) - | 78 | 57 | 61 |
|
| ||||||||
| 2-Stage infection free survival rate % | 1.) 75 | - | - | 58 | 1.) - | 1.) 87 | 83 | 83 |
|
| ||||||||
| 1-Stage infection free survival rate % | - | - | - | 100 | - | - | - | - |
|
| ||||||||
| Resection arthroplasty infection free survival rate % | - | - | - | - | 1.) 51 | 1.) 49 | - | - |
|
| ||||||||
| Outcome | With combined or broad-spectrum antibiotics, two-stage revision showed comparable outcome in satisfaction rates, reinfections rates and cumulative survival rates at 5-year Follow-up with CP PJI patients. | The success rate of infection control was higher in the CN group, which suggests that CN may not necessarily be a negative prognostic factor for PJI. | - | The overall infection control rate was similar between CP and CN PJI cases (both 73%). | The outcome of CN PJI is similar to the outcome of PJI due to known pathogens. | The demographics and outcome of CP and CN PJI patients were similar (free of treatment failure at 2 years 79% and 75%). | The infection control rates and clinical outcomes were not different between CP and CN groups (overall infection control rates 90% and 95%). | Overall rates of infection control, successful treatment, and functional outcomes were not different between the CP and CN groups (overall infection control rates 90% and 95%). |
Figure 1Flow chart.
Figure 2Range of incidence of CN PJI.
Figure 3Rates of incidence for culture-negative periprosthetic joint infections of the hip and the knee. Summary estimates for the incidence of CN PJI were calculated using random-effects models with 95% confidence interval (CI). An I2 value (statistical heterogeneity) of 0.00% indicates a low variability in intrastudy differences in the overall effect size.
Figure 4Funnel plot analyses.
Figure 5Definition of diagnosis of culture-negative periprosthetic joint infections.
Figure 6Definition of successful treatment.
Different diagnostic criteria for periprosthetic joint infections [3–13].
| Parameter | MSIS criteria | AAOS | Philadelphia Consensus | Parvizi et al. | Aggarwal et al. [ | Zimmerli et al. | Trampuz et al. | Tohtz et al. [ | Atkins et al. | Portillo et al. | Shanmugasundaram et al. [ | Müller et al. | Spangehl et al. [ | Tohtz et al. | Aggarwal et al. | Shanmugasundaram et al. | Spangehl et al. | Charité (modified from Zimmerli) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||||||
| Sinus tract or abscess | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |
| Pain or poor functional status | x | x | x | x | x | x | ||||||||||||
| Erythema or swelling | x | x | x | x | x | |||||||||||||
| Pus | x | x | x | x | x | x | ||||||||||||
| Early loosening | x | |||||||||||||||||
|
| ||||||||||||||||||
| CRP | x | x | x | x | x | x | x | x | x | x | x | |||||||
| ESR | x | x | x | x | x | x | x | x | x | x | x | |||||||
| Leucocytes | x | x | x | |||||||||||||||
|
| ||||||||||||||||||
| Acute infection | x | x | x | x | x | x | x | x | x | x | x | x | x | |||||
| Acute infection | x | x | x | |||||||||||||||
| Granulocytes/HPF | x | x | x | x | x | x | x | x | x | x | x | x | ||||||
|
| ||||||||||||||||||
| ≥2 culture-positive samples | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | |||
| 1 culture-positive sample | x | x | x | x | x | x | x | |||||||||||
| 1 culture-positive sample | x | x | ||||||||||||||||
|
| ||||||||||||||||||
| ≥ 50 colonies/ml | ||||||||||||||||||
|
| ||||||||||||||||||
| Leucocytes | x | x | x | x | x | x | x | x | x | |||||||||
| Granulocytes | x | x | x | x | x | x | x | x | x | |||||||||
| Pus | x | x | x | x | x | x | x | x | x | x | x | x | x | |||||
| Culture positive | x | x | x | x | x | x | x | x | ||||||||||
| Main criteria | ||||||||||||||||||
| Secondary criteria |
Diagnostic parameters for CN PJI [23].
|
|
|
|
|
|---|---|---|---|
|
| Sinus tract (fistula) | 20-30% | 100% |
|
| |||
|
| >2000/ul leucocytes | ≈90% | ≈95% |
|
| |||
|
| Inflammation (≥23 granulocytes per 10 high-power fields) | 73% | 95% |
|
| |||
|
| Microbial growth in: | 45-75% | 95% |
aMetal-on-metal bearing components can simulate pus (≪pseudopus≫), leukocyte count is usually normal (visible is metal debris)
bLeukocyte count can be high without infection in the first 6 weeks after surgery, in rheumatic joint disease (including crystalopathy), periprosthetic fracture or luxation.
Leukocyte count should be determined within 24 h after aspiration by microscopy or automated counter; clotted specimens are treated with 10 μl hyaluronidase
cClassification after Krenn and Morawietz: PJI corresponds to type 2 or type 3
dFor highly virulent organisms (e.g. S. aureus, streptococci, E. coli) or patients under antibiotics, already one positive sample confirms infection
eUnder antibiotics, for S. aureus and anaerobes, <50 CFU/ml can be significant
Antimicrobial treatment in CN PJI [23].
|
|
|
|
|
|---|---|---|---|
| (red: difficult-to-treat) | (check pathogen susceptibility before) | (italic font: | |
|
| Ampicillin/sulbactamc |
| i.v. |
| for 2 weeks, followed by: | |||
| Rifampind + Levofloxacin | 2 × 450 mg | p.o. | |
|
| p.o. |
a Total duration of therapy: 12 weeks, usually 2 weeks intravenously, followed by oral route.
bLaboratory testing 2x weekly: leukocytes, CRP, creatinine/eGFR, liver enzymes (AST/SGOT and ALT/SGPT). Dose-adjustment according to renal function and body weight (<40/> 100kg).
c Penicillin allergy of NON-type 1 (e.g., skin rash): cefazolin (3 × 2 g i.v.). In case of anaphylaxis (= type 1 allergy such as Quincke's edema, bronchospasm, and anaphylactic shock) or cephalosporin allergy, vancomycin (2 × 1 g i.v.) or daptomycin (1 × 8 mg/kg i.v.).
Ampicillin/sulbactam is equivalent to amoxicillin/clavulanic acid (3 × 2.2 g i.v.).
d Rifampin is administered only after the new prosthesis is implanted. Add it already to intravenous treatment as soon as wounds are dry and drains removed; in patients aged >75 years, rifampin is reduced to 2 × 300 mg p.o.